{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-23-000014","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.580483+00:00","generated_at":"2026-06-16T10:38:51.182450+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead Q1: ex-Veklury product sales +15% to $5.7B; lowers GAAP EPS guidance to $4.75-$5.15","bullets":["Q1 total revenue $6.4B (-4% YoY); product sales ex-Veklury up 15% to $5.7B.","HIV sales $4.2B (+13%); Biktarvy sales $2.7B (+24%); Oncology sales $670M (+59%).","Non-GAAP diluted EPS $1.37 vs $2.12 YoY; GAAP EPS $0.80 vs $0.02.","GAAP EPS guidance lowered to $4.75-$5.15 from $5.30-$5.70; non-GAAP unchanged $6.60-$7.00.","Cash & equivalents $7.2B; paid $969M dividends, repurchased $400M stock in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-23-000014","json":"https://secwatch.observer/filing/0000882095-23-000014.json","markdown":"https://secwatch.observer/filing/0000882095-23-000014.md","text":"https://secwatch.observer/filing/0000882095-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/0000882095-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/gild-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T10:38:51.182450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6c5541f1f35bff714c6a59b4104cd38c7e00aee","claim":"GILEAD SCIENCES, INC. reported first quarter of 2023 results: EPS Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022.","evidence_excerpt":"Total first quarter 2023 revenue decreased 4% to $6.4 billion compared to the same period in 2022, due to lower Veklury® (remdesivir) sales, partially offset by increased sales in HIV and Oncology.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/0000882095-23-000014-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"EPS","value":"Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e6c5541f1f35bff714c6a59b4104cd38c7e00aee","claim":"GILEAD SCIENCES, INC. reported first quarter of 2023 results: EPS Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022.","evidence_excerpt":"Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000014/0000882095-23-000014-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"EPS","value":"Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}